CEO Executive AssistantHealth Technology Assessment has graduated from a post-approval problem to a core development strategy constraint. CEOs who still treat HTA as a late-stage commercial challenge are watching programs achieve regulatory approval only to face restricted reimbursement, protracted negotiation, or outright rejection by NICE, G-BA, HAS, and their counterparts across the markets that determine whether a drug becomes a commercial success. The evidence base that HTA bodies require is built or missed in decisions made years before any value dossier lands on a committee’s desk.
For pharma and biotech CEOs, this reality carries a direct implication for how personal time is allocated. HTA strategy is not a function that can be delegated entirely to market access or health economics teams and picked up again at the point of submission. It requires CEO-level engagement at the development decisions where the fundamental trade-offs are made, and it requires the CEO to manage the organizational tension that those trade-offs consistently generate between clinical ambition and economic evidence requirements.
This article addresses where and how CEOs must invest personal time in HTA strategy, why the organizational dynamics make CEO involvement irreplaceable, and what the practical framework for that involvement looks like across the development lifecycle.
Why HTA Strategy Demands CEO-Level Attention
The case for CEO involvement in HTA strategy begins with the stakes. In the major European markets, HTA outcomes directly determine whether a drug is reimbursed, at what price, and with what patient population restrictions. NICE appraisals in England, G-BA benefit assessments in Germany, HAS evaluations in France, and equivalent processes in Italy, Spain, Sweden, and the Netherlands collectively govern access to several hundred million patients and tens of billions in annual pharmaceutical revenue.
These outcomes are increasingly determined by decisions made during clinical development, not by the quality of the submission or the sophistication of the health economics model. The comparative evidence base, the endpoints selected, the comparators used in trials, the patient populations enrolled, the duration of follow-up, and the quality of life data collected are all design choices made years before market authorization. By the time an HTA submission is being prepared, most of the decisions that will determine its outcome have already been made.
This is the fundamental reason why HTA strategy cannot be treated as a commercial function operating downstream of R&D. It requires integration into clinical development governance at the point where those decisions are being made, and that integration requires CEO-level attention because the trade-offs involved consistently pit the interests of different organizational functions against each other in ways that only the CEO can resolve.
The Organizational Tension at the Core
The tension is structural and predictable. R&D organizations optimize for regulatory approval. Their clinical programs are designed to demonstrate efficacy and safety to the FDA and EMA. The endpoints, comparators, and patient populations that maximize the probability of regulatory success are often different from those that would generate the strongest HTA evidence package.
Clinical teams resist changes to trial design that they perceive as increasing complexity, cost, or risk to the primary regulatory endpoint. Health economics teams advocate for additional endpoints, longer follow-up, and broader comparator sets that the clinical teams view as unnecessary for regulatory purposes and potentially harmful to trial conduct. Commercial teams want broad label claims that may require patient populations where HTA bodies have limited willingness to pay.
No one below the CEO has the authority to resolve these tensions consistently across a portfolio. This is not a failure of organizational design; it reflects that the trade-offs involve genuine conflicts between legitimate organizational interests. The CEO’s role is to set the standard, create the governance that surfaces these conflicts early, and make or enforce the decisions that resolve them.
Aligning Trial Design With HTA Evidence Requirements
The single highest-leverage point for CEO time investment in HTA strategy is clinical trial design governance. This is where the evidence base that will determine HTA outcomes is built or compromised, and it is where the organizational tensions described above are most acute.
Early HTA Engagement as a Development Standard
Leading pharmaceutical organizations have established the principle that HTA considerations should enter clinical development planning at the point of indication selection and proof-of-concept design, not at the point of Phase III protocol finalization. This means seeking scientific advice from HTA bodies early in development, incorporating HTA feedback into Phase II endpoint selection, and treating the HTA evidence package as a co-equal design objective alongside regulatory requirements.
For this to happen consistently across a portfolio, it must be a CEO-level expectation, not a practice that individual program teams adopt selectively. CEOs who have embedded this standard into their development governance processes report that it changes the quality of conversations in pipeline reviews: teams come prepared to explain how their clinical program will support not just regulatory approval but HTA value demonstration.
The practical implication for CEO time is participation in the governance touchpoints where these standards are applied. This does not mean attending every clinical development committee meeting. It means ensuring that pipeline reviews, development candidate decisions, and Phase II to Phase III transition decisions explicitly address HTA alignment, and that the CEO asks the questions that create accountability for this standard.
Scientific Advice From HTA Bodies
NICE offers scientific advice services. The G-BA participates in joint scientific consultations under the European Medicines Agency framework. HAS and other HTA bodies have formal and informal mechanisms for early dialogue. Engaging these mechanisms systematically, and ensuring that the output actually shapes development decisions, is an organizational capability that requires CEO-level prioritization.
Many pharmaceutical organizations have health economics and market access functions that are theoretically responsible for HTA scientific advice engagement but lack the organizational authority to ensure that advice is incorporated into development decisions when doing so creates tension with clinical priorities. CEOs who personally review the outcomes of HTA scientific advice interactions and ask specifically how those outcomes have shaped protocol design create the accountability that makes HTA scientific advice into a genuine development input rather than a compliance exercise.
Comparative Effectiveness and Active Comparators
One of the most consequential HTA-driven design decisions involves comparator selection. HTA bodies, particularly the G-BA under AMNOG, require evidence of additional benefit compared to the appropriate comparator therapy (zweckmassige Vergleichstherapie). The appropriate comparator is defined by the HTA body, not by the drug developer, and it is often a specific existing treatment rather than placebo.
Running active comparator trials is more expensive and more complex than placebo-controlled trials. It creates regulatory risk if the comparator arm performs better than anticipated. Clinical teams have legitimate reasons to resist it. But failing to provide direct comparative evidence against the comparator that an HTA body will use as its reference point is one of the most common causes of restricted reimbursement and price reductions in the major European markets.
Resolving this tension requires CEO-level authority in most organizations. It involves committing additional development resources, accepting additional trial risk, and potentially constraining the clinical ambition of a program in order to build the evidence base that HTA bodies require. The market access strategy implications of this decision extend across the entire commercial trajectory of the asset.
Managing Value Dossier Strategy
The value dossier is the document through which a pharmaceutical company presents its evidence to an HTA body and makes the case for reimbursement. The quality of this document matters. The evidence it contains matters far more. But the strategic framing of that evidence, the narrative that connects clinical trial outcomes to the value proposition that the HTA body is being asked to accept, is where CEO-level strategic judgment has genuine leverage.
The CEO’s Role in Value Narrative
HTA bodies are not simply evaluating whether a drug works. They are evaluating whether it works well enough, in the right patients, compared to the right alternatives, at a price that represents acceptable value to the health system. The value narrative in a dossier is a strategic argument that addresses all of these dimensions simultaneously.
Effective value narratives require decisions about how to frame the clinical evidence, which patient subgroups to emphasize, how to characterize the existing treatment landscape, and how to present health economic modeling assumptions. These decisions have significant consequences for HTA outcomes, and they require the same strategic judgment that CEOs apply to investor communications and regulatory strategy.
CEOs who engage personally in value dossier strategy review, at the level of the strategic argument rather than the technical detail, improve the quality of the narrative and signal to the organization that HTA outcomes are a CEO-level priority. This matters because the talent and organizational attention that an organization brings to HTA submissions reflects the priority it assigns to them.
Coordinating Across HTA Bodies
A drug seeking reimbursement across multiple European markets faces a sequence of HTA processes that are legally independent but practically interconnected. Outcomes in early-filing countries influence negotiations in later ones. The evidence package and value narrative that succeeds with NICE may require adaptation for the G-BA’s different methodological requirements. HAS uses a different clinical added value framework from either.
Managing this sequence strategically requires early decisions about which markets to file in which order, how to adapt the value narrative for different HTA methodological frameworks, and how to manage the risk that an unfavorable outcome in one market undermines negotiations in others. These are genuinely strategic decisions that benefit from CEO-level involvement, particularly for programs where the commercial stakes are high and the HTA risk is material.
The drug pricing strategy implications of cross-market HTA sequencing are significant: reference pricing mechanisms mean that a low negotiated price in one market can become the reference point for negotiations in others, creating a commercial consequence from HTA decisions that extends well beyond the market where the decision was made.
Navigating the Clinical Ambition Versus Economic Evidence Trade-Off
The tension between clinical ambition and HTA evidence requirements is perhaps the most important organizational dynamic that CEOs must manage in pharmaceutical development. It is also one of the least acknowledged.
Clinical ambition in drug development means pursuing the broadest possible indication, the most favorable patient population, and the endpoints that demonstrate the most striking treatment benefit. These objectives are not wrong; they reflect genuine commitments to scientific excellence and patient benefit. But they sometimes conflict directly with what HTA bodies need to see in order to grant broad, unrestricted reimbursement at a price that supports the commercial model.
Where the Trade-Off Bites
The trade-off is most acute in three scenarios. First, indication breadth: a program that seeks a broad indication covering heterogeneous patients may achieve regulatory approval but face HTA bodies that restrict reimbursement to the subpopulation where evidence of benefit is strongest. Second, endpoint selection: programs that use surrogate endpoints or biomarker-based outcomes to maximize regulatory approval probability may face HTA bodies that require evidence on clinical outcomes and quality of life before granting full reimbursement. Third, comparator choice: programs designed to beat placebo face HTA bodies that require comparative evidence against active treatments.
In each scenario, the clinical development team is making rational decisions given their objectives, which are primarily regulatory. The CEO’s role is to ensure that HTA objectives are built into the development team’s mandate from the beginning, and that the trade-offs between regulatory optimization and HTA optimization are made explicitly rather than by default.
Creating the Governance Structure
The most effective CEOs in this space have established governance structures that require explicit HTA impact assessment at major development decision points. This means that before a Phase III protocol is finalized, the development team must demonstrate that the design has been reviewed against HTA requirements for the major markets, that any conflicts between regulatory optimization and HTA optimization have been identified, and that the resolution of those conflicts has been deliberated at the appropriate level.
According to research published by the ISPOR Special Interest Group on HTA, organizations that integrate HTA considerations into early clinical development consistently achieve better reimbursement outcomes and faster time to patient access than those that treat HTA as a post-approval activity. The difference is not primarily in the quality of the value dossier; it is in the quality of the underlying evidence base.
The CEO’s Practical Time Investment
Translating this strategic argument into a practical time allocation requires specificity. CEO involvement in HTA strategy does not mean becoming a health economist or attending technical dossier preparation meetings. It means investing time at the points where strategic decisions are made and organizational trade-offs are resolved.
Quarterly portfolio reviews should include explicit HTA readiness assessment for programs approaching Phase III and late-stage development. Annual strategic planning should address the HTA landscape in priority markets and the investment required to build the evidence base for the pipeline. Individual program milestones at Phase II completion and Phase III initiation should require explicit HTA alignment sign-off. Value dossier strategy for major programs should involve CEO review of the strategic argument, not the technical appendices.
Across these touchpoints, the time investment is concentrated and high-leverage. A CEO who brings genuine HTA literacy to these conversations and asks consistently about the evidence base being built for market access, not just regulatory approval, creates organizational accountability that compounds across every program in the portfolio.
Conclusion
Health Technology Assessment is the mechanism through which pharmaceutical innovation translates into patient access and commercial success in most of the world’s major markets. The evidence base that determines HTA outcomes is built during clinical development, through decisions that create persistent organizational tension between regulatory optimization, clinical ambition, and economic evidence requirements.
CEOs who treat HTA strategy as a late-stage commercial problem will continue to discover, too late, that the evidence they needed was never collected. CEOs who embed HTA alignment into development governance, manage the organizational trade-offs that alignment requires, and invest personal time in value dossier strategy for their most important programs will build a systematic market access advantage that compounds across the pipeline.
The time investment this requires is specific, manageable, and concentrated at the highest-leverage decision points in the development process. The commercial and patient access returns on that investment are among the most significant available to a pharma or biotech CEO today.